Intellectual Property India Publishes Patent Application for 'Nucleoside Analog For 5'-Phosphonate Modification And Oligonucleotide Prepared Therefrom' Filed by Shanghai Argo Biopharmaceutical Co. Ltd.

MUMBAI, India, Oct. 24 -- Intellectual Property India has published a patent application (202547092916 A) filed by Shanghai Argo Biopharmaceutical Co. Ltd., Shanghai, on Sept. 27, for 'nucleoside analog for 5'-phosphonate modification and oligonucleotide prepared therefrom.'

Inventor(s) include Shao, Pengcheng Patrick; Shu, Dongxu; and Gu, Kaichun.

The application for the patent was published on Oct. 24, under issue no. 43/2025.

According to the abstract released by the Intellectual Property India: "The present invention relates to a nucleoside analog for 5' modification and an oligonucleotide prepared therefrom, and more particularly to a modification nucleoside and an analog thereof that can be incorporated into the end of an oligonucleotide, and may be incorporated into a double-stranded oligonucleotide (short interfering RNA) or single-stranded oligonucleotide (e.g., an antisense oligonucleotide). The oligonucleotide provided is expected to hybridize with a portion of a target RNA, thereby resulting in loss of the normal function of the target RNA."

The patent application was internationally filed on Apr. 03, 2024, under International application No.PCT/CN2024/085752.

Disclaimer: Curated by HT Syndication.